Add Row
Add Element
cropper
update
PractitionersOfHealth - a CapidHouser.com media site
update
Add Element
  • Home
  • Categories
    • dentistry
    • cosmetics
    • opticians
    • physiotherapy
    • chiropractor
    • osteopathy
  • Massage Therapy
  • Yoga Therapy
  • diet and nutrition
  • reflexology
June 23.2025
2 Minutes Read

Aesthetic Surgery Journal Soars to New Heights with Record Impact Factors

Upward trend chart on easel representing Aesthetic Surgery Journal impact factor growth.

The Rise of Aesthetic Surgery Journal and ASJ Open Forum

In a remarkable advancement for the field of aesthetic surgery, the Aesthetic Surgery Journal (ASJ) has increased its impact factor from 3.1 to an impressive 3.9, earning the top spot in its specialty. Meanwhile, its open-access companion, ASJ Open Forum, recently achieved a notable rise in its impact factor from 1.6 to 1.9, marking the journal’s second citation score. These figures, reported by Clarivate in their Journal Citation Reports, are significant indicators of the academic influence and quality of research produced by these journals.

Understanding Impact Factors and Their Importance

The impact factor of a journal reflects the average number of citations received by its published articles over a two-year period. It’s an essential metric used by scholars, researchers, and practitioners to gauge the relevance and credibility of scientific work. High impact factors generally indicate that a journal's articles are widely referenced, a clear testament to the quality and importance of the research shared within its pages.

Innovation and Quality in Aesthetic Research

Jeffrey M. Kenkel, MD, editor-in-chief of ASJ, credits the journal’s success to the rigorous standards upheld by the editorial team and the outstanding contributions of its authors. “We are honored by this recognition as we continue to raise the standard for academic excellence in aesthetic surgery,” he states. This commitment to quality serves as a beacon for those seeking the best cosmetic procedures, ensuring that healthcare professionals and the clients they serve can trust the latest research findings.

A Broader Reach with ASJ Open Forum

ASJ Open Forum, established in January 2019 and published through Oxford University Press, aims to provide diverse formats of high-quality aesthetic research. From case reports to expert commentaries, the platform facilitates knowledge sharing among practitioners, thus contributing significantly to ongoing education in the field. Al Aly, MD, editor-in-chief of ASJ Open Forum, emphasizes, “Achieving a second Impact Factor is a meaningful validation of our mission to broaden access to high-quality aesthetic research.”

Engagement Initiatives: Bridging Practitioners and Patients

Both journals are dedicated not only to publishing cutting-edge research but also to fostering conversations surrounding aesthetic practices. Through initiatives like the ASJ Journal Club and GEMS webinars, they invite readers and authors to discuss emerging topics and enhance their knowledge in aesthetic surgery. Visual abstracts and video content also make the research more accessible, allowing potential clients to grasp complex subjects easily.

The Future of Aesthetic Surgery Publications

As both ASJ and ASJ Open Forum continue to develop their outreach and educational tools, the trajectory of aesthetic surgery research looks promising. Together, they stand as pillars of knowledge and innovation, advancing the field while equipping cosmetic surgery practices and patients alike with the latest evidence-based insights.

cosmetics

2 Views

0 Comments

Write A Comment

*
*
Related Posts All Posts
07.04.2025

FDA Extends Opzelura Review: Hope for Pediatric Atopic Dermatitis Treatment

Update FDA’s Extended Review: Implications for Pediatric Atopic Dermatitis TreatmentThe recent announcement by Incyte regarding the FDA’s extension of the review period for Opzelura, a topical treatment for atopic dermatitis in children aged 2-11, has significant implications for young patients and their families. For many parents, the frustration of watching their child struggle with a chronic skin condition can be overwhelming. This extension, now pushing the Prescription Drug User Fee Act action date to September 19, 2025, means there’s still hope for new treatment avenues amidst increasing numbers of children diagnosed with atopic dermatitis.Understanding Atopic DermatitisAtopic dermatitis is more than just skin deep; it's linked to immune system responses, and managing its symptoms can be challenging. Millions of children in the U.S. deal with this condition, leading to potential sleepless nights and discomfort. Steven Stein, MD, the chief medical officer at Incyte, emphasizes the importance of innovative treatments like ruxolitinib cream, which could offer relief without the steroids typically prescribed for such conditions.Positive Results from Clinical TrialsThe optimism surrounding Opzelura stems from its Phase 3 TRuE-AD3 study, which showcased significant treatment success compared to vehicle (non-medicated) controls. In the study, higher rates of treatment efficacy were recorded, which is essential information for parents seeking effective solutions for their children’s condition. Potential new remedies that minimize reliance on steroids could pave the way for enhanced treatment options.Addressing Safety ConcernsWhen it comes to any new treatment, the safety profile is paramount. Opzelura demonstrated no new safety signals during the trial, and it did not lead to severe adverse events. Learning that the most common side effect—application site pain—was mild and transient offers reassurance to parents exploring treatment options for their young ones.Why Parents Should Stay InformedAs a parent, staying informed about new treatments like Opzelura can be invaluable. Understanding available options, such as which pediatric plastic surgery specialists are trusted for related conditions or how to navigate cosmetic approaches, can empower parents to make informed health decisions for their children. As the FDA continues to evaluate Opzelura's application, the hope is that it will lead to new, safe, and effective treatments for pediatric atopic dermatitis, reducing the hardship many families face daily.

07.04.2025

Opzelura Review Extension: What It Means For Kids with Atopic Dermatitis

Update New Hope for Kids Struggling with Atopic DermatitisThe recent announcement from Incyte regarding their topical treatment, Opzelura, brings a ray of hope for children aged 2 to 11 suffering from atopic dermatitis. This chronic and uncomfortable skin condition affects millions of children in the United States, making effective treatments highly sought after. With the FDA extending the review period to September 19, 2025, more time will be devoted to scrutinizing the chemistry and manufacturing of this promising new drug.Understanding the Importance of OpzeluraCurrent treatments for atopic dermatitis primarily include topical steroids, which can have side effects, especially in young patients. The potential availability of Opzelura as a non-steroidal topical treatment could significantly improve the quality of life for many families. This move towards a less invasive treatment option aligns with broader health trends favoring approaches with fewer complications.What Parents Should Know About Atopic DermatitisAtopic dermatitis can be challenging not only for the child but also for parents who witness their child suffering. Dr. Steven Stein, the Chief Medical Officer at Incyte, emphasizes the vital need for effective non-steroidal treatments. Given Opzelura’s positive results from the TRuE-AD3 study, this cream shows promise, achieving significant treatment success and demonstrating an overall safe profile.Examining the Efficacy of OpzeluraThe Phase 3 study revealed compelling outcomes: children treated with Opzelura had a noticeable improvement in their condition compared to those using a non-medicated cream. In particular, over 75% of patients demonstrated significant improvements in their eczema severity within just eight weeks. Such rapid results can alleviate worry for parents seeking effective solutions.The Future of Pediatric Dermatological TreatmentsThe extended review period also indicates a commitment to ensuring that the drug, once approved, meets the highest standards for safety and efficacy. As families look for trustworthy options for their children’s skin conditions, this could guide parents in their search for the best cosmetic and dermatological care. The anticipation surrounding Opzelura signals a shift in how we might approach not just atopic dermatitis treatment, but also other pediatric skin conditions in the future.As the future unfolds, parents and caregivers are encouraged to stay informed and involved as the FDA navigates its review process. Keeping an eye on upcoming developments can empower families to ask the right questions and pursue the best treatment avenues for their children.

07.04.2025

FDA Delays Decision on Opzelura: What Parents Should Know About Pediatric Atopic Dermatitis

Update The FDA's Deliberation: What It Means for Children's Health The U.S. Food and Drug Administration (FDA) has extended its review period for the supplemental New Drug Application (sNDA) of Opzelura, a topical cream by Incyte intended for treating mild to moderate atopic dermatitis in children aged 2 to 11. This extension, moving the action date to September 19, 2025, allows the FDA crucial time to review additional data concerning the product's manufacturing and controls. Understanding Atopic Dermatitis in Children Atopic dermatitis is a chronic skin condition that affects millions of children across the U.S., often leading to discomfort and distress. Dr. Steven Stein, Incyte’s chief medical officer, emphasizes the necessity for innovative treatment options that do not rely on steroids, which are commonly prescribed but can have side effects. With the global incidence of atopic dermatitis rising, the potential approval of Opzelura could offer an alternative therapeutic strategy for families coping with this condition. Positive Signs from Clinical Trials The green light for Opzelura came after promising results from the phase 3 TRuE-AD3 clinical trial. This study illustrated that significantly more children receiving Opzelura achieved notable improvements in their skin conditions compared to those using a non-medicated control cream. Among the specific measures, 75% demonstrated substantial improvement in the Eczema Area and Severity Index after eight weeks of treatment. The Journey Ahead for Families and Healthcare Providers As families eagerly await FDA's final decision, the extended review period provides a moment of reflection. This protracted timeline urges parents to consider the broader implications of children's health and the importance of reliable, effective treatments that ground themselves in safety and efficacy. As we anticipate the upcoming decision, it also highlights a vital reality: the transformative effect that a new treatment option can have on the lives of children and their families. For parents searching for the best practices to manage their child's health, staying informed about advancements like Opzelura is crucial. If you have a child suffering from atopic dermatitis, consider discussing these developments with your healthcare provider, as they can provide insights tailored to your child’s specific health needs.

Add Row
Add Element
cropper
update
PractitionersOfHealth
cropper
update

Write a small description of your business and the core features and benefits of your products.

  • update
  • update
  • update
  • update
  • update
  • update
  • update
Add Element

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6
Add Element

+447974613172

AVAILABLE FROM 8AM - 5PM

City, State

, ,

Add Element

ABOUT US

Write a small description of your business and the core features and benefits of your products.

Add Element

© 2025 CompanyName All Rights Reserved. Address . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*